Related Experiment Video

Updated: Oct 25, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.8K

Present and Future Research on Anal Squamous Cell Carcinoma

Laurie Spehner1,2, Jihane Boustani3, Luc Cabel4

  • 1Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique Research Unit INSERM UMR1098, University of Bourgogne Franche-Comté, 25020 Besançon, France.

Cancers
|August 7, 2021
PubMed

Insights

Advances in anal squamous cell carcinoma treatment are emerging, with new chemotherapy, immunotherapy, and HPV ctDNA biomarkers improving prognosis and guiding treatment strategies for this rare cancer.

Area of Science:

  • Oncology
  • Cancer Research

Background:

  • Anal squamous cell carcinoma (aSCC) is a rare cancer with limited treatment advancements over the past three decades.
  • The majority of aSCC cases are associated with HPV genotype 16.

Purpose of the Study:

  • To summarize recent progress and future directions in the treatment and understanding of anal squamous cell carcinoma.
  • To highlight the impact of novel therapeutic strategies and biomarkers in managing this orphan disease.

Main Methods:

  • Review of ongoing clinical trials investigating combination therapies for localized and advanced aSCC.
  • Discussion of the role of emerging biomarkers, such as HPV circulating tumor DNA (ctDNA), in prognostic assessment and treatment guidance.

Main Results:

  • Significant momentum in aSCC research driven by taxane-based chemotherapy and immunotherapy.
  • Approximately 20 clinical trials are evaluating anti-PD1/L1 combinations with radiotherapy, chemotherapy, vaccines, and other targeted agents.
  • HPV ctDNA liquid biopsy shows high sensitivity and specificity for improved prognostic measurement and treatment strategy guidance.

Conclusions:

  • The landscape of anal squamous cell carcinoma treatment is rapidly evolving with new therapeutic options.
  • Emerging biomarkers like HPV ctDNA are crucial for personalized medicine approaches in aSCC.
  • Continued research into potential molecular targets is essential for future clinical advancements in HPV-related aSCC.
Keywords:
anal carcinomabiomarkerschemotherapyimmunotherapyresearchtrials

More Related Videos

Author Spotlight: Unlocking the Mysteries of Oral Potential Malignancies05:42

Author Spotlight: Unlocking the Mysteries of Oral Potential Malignancies

Published on: August 11, 2023

1.3K
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

10.0K

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
481
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K